We are actively promoting the central management of medication information using our electronic medication notebook, Okusuri Techo Plus, which provides medication guidance tailored to each patient, cooperates with medical institutions, and enhances post-dispensing consultations and follow-ups. We were among the first in the industry to expand online healthcare services, using our in-house developed online pharmacy service NiCOMS and handle electronic prescriptions. Further, to provide higher quality medical services to patients, many of our pharmacies have obtained certifications as specialized medical institution cooperation pharmacies and regional cooperation pharmacies ahead of industry peers. As such, we focus on developing pharmacies that serve as hubs for local medical institutions and advanced medical care, while also cultivating highly specialized pharmacists.
In the Pharmaceutical Manufacturing and Sales Business, the target of "80% or more in all prefectures by the end of FY2029, while ensuring the reliability of quality and stable supply of generic drugs" as the percentage of generic drugs used by volume remains unchanged. In addition, a new secondary target of "at least 65% of the market share of generic drugs by the end of FY2029" has been set, and the promotion of generic drugs is still required. On the other hand, the generic drug industry is undergoing a period of major change, with NHI price revisions in intermediate years in addition to the regular biennial NHI price revisions from FY2021 onward. In such an environment, as generic drugs become more widely available, there is an increasing need to develop and strengthen systems for ensuring a stable supply and reliability of quality, as well as for collecting and providing information. As a company that aims to be "The most trusted partner in healthcare” by 2030, we recognize that we have a social responsibility to fulfill in meeting these demands. We will continue to prioritize quality management and the stable supply of generic drugs while continuing to add to the new NHI drug price list, by investing in R&D. We will also take measures to enhance productivity.
In the medical professional staffing and placement business, market demand for the pharmacist business is shifting dramatically from temporary staffing to placement due to the launch of the Family Pharmacist System. The Group has been quick to seize on this change in demand and shift from the temporary staffing business to the placement and referral business, and is working to expand its share of the pharmacist business by raising awareness of the Medical Resource brand. In addition, in the physician business, we have been strengthening our efforts since 2017 to expand nationwide. Furthermore, against the backdrop of the growing importance of health management at domestic companies, we will promote the expansion of our healthcare business, including occupational physician services, and we will continue to work on further business expansion to meet the demands of the human resources market. The Group will continue to expand its business to meet the demands of the human resources market.
The Group aims to overcome major changes in the business environment and promote structural reforms through a business portfolio strategy aimed at achieving high profitability and management based on ROIC, while further promoting DX and utilizing AI to improve labor productivity and, ultimately, capital efficiency. In addition, we will accelerate the promotion of human capital management, which is one of the most important issues for the realization of our Long-Term Vision 2035. In addition, based on our new group philosophy, our mission, "To give people the closest possible support," we will strengthen our sustainability management and contribute to the development of a sustainable society through the resolution of social issues.
